TECVAYLI Demonstrates Potential as Frontline Combination Therapy for Patients
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy Johnson & Johnson announced new frontline...